Q4 EPS Estimate for Sarepta Therapeutics Boosted by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at Zacks Research boosted their Q4 2024 earnings estimates for shares of Sarepta Therapeutics in a report issued on Monday, February 3rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $1.24 for the quarter, up from their prior forecast of $1.00. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.65 EPS, Q3 2025 earnings at $2.61 EPS, Q4 2025 earnings at $2.88 EPS, FY2025 earnings at $10.04 EPS, Q1 2026 earnings at $3.06 EPS, Q2 2026 earnings at $3.58 EPS, Q3 2026 earnings at $3.56 EPS, Q4 2026 earnings at $3.60 EPS and FY2026 earnings at $13.80 EPS.

A number of other research firms have also recently weighed in on SRPT. Guggenheim increased their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Robert W. Baird reduced their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. Finally, Raymond James restated an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Trading Down 5.8 %

NASDAQ SRPT opened at $112.11 on Thursday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock’s 50-day moving average is $121.56 and its 200-day moving average is $126.35. Sarepta Therapeutics has a one year low of $102.15 and a one year high of $173.25. The firm has a market cap of $10.71 billion, a P/E ratio of 89.69 and a beta of 0.75.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Inceptionr LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $1,326,000. Arizona State Retirement System lifted its position in Sarepta Therapeutics by 1.6% in the fourth quarter. Arizona State Retirement System now owns 24,890 shares of the biotechnology company’s stock valued at $3,026,000 after purchasing an additional 394 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in Sarepta Therapeutics during the 4th quarter valued at $3,829,000. Assetmark Inc. increased its holdings in Sarepta Therapeutics by 9.6% during the 4th quarter. Assetmark Inc. now owns 42,759 shares of the biotechnology company’s stock valued at $5,199,000 after purchasing an additional 3,734 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in shares of Sarepta Therapeutics by 34.0% during the fourth quarter. Victory Capital Management Inc. now owns 88,808 shares of the biotechnology company’s stock valued at $10,798,000 after acquiring an additional 22,529 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.